Cargando…

Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy

To assess the predictive and prognostic significance of folate receptor (FR)-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) received first-line chemotherapy. Eligible patients with chemotherapy-naïve, unresectable SCLC were enrolled and blood samples were coll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Jiqiao, Zhao, Jing, Jiang, Tao, Li, Xuefei, Zhao, Chao, Su, Chunxia, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564747/ https://www.ncbi.nlm.nih.gov/pubmed/28467771 http://dx.doi.org/10.18632/oncotarget.17039

Ejemplares similares

Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
por: Chen, Xiaoxia, et al.
Publicado: (2020)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

Folate receptor‐positive circulating tumor cells in the preoperative diagnosis of indeterminate pulmonary nodules
por: Li, Zhixin, et al.
Publicado: (2022)

Preoperative levels of folate receptor-positive circulating tumor cells in different subtypes of early-stage lung adenocarcinoma: Predictive value for determining extent of surgical resection
por: Zhou, Chao, et al.
Publicado: (2023)

Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer
por: Jia, Yijun, et al.
Publicado: (2017)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
por: Coco, Simona, et al.
Publicado: (2017)

The value of folate receptor‐positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics
por: Xu, Yunjian, et al.
Publicado: (2023)

Clinical value of folate receptor-positive circulating tumor cells in patients with esophageal squamous cell carcinomas: a retrospective study
por: Zhou, Qiang, et al.
Publicado: (2023)

Detection of folate receptor‐positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer
por: Wu, Qian, et al.
Publicado: (2021)

Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Nicolazzo, Chiara, et al.
Publicado: (2017)

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma
por: Jiang, Tao, et al.
Publicado: (2021)

The utility of folate receptor-positive circulating tumor cell in cancer diagnosis in the elderly population
por: Li, Na, et al.
Publicado: (2019)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Synthesis of folate-chitosan nanoparticles loaded with ligustrazine to target folate receptor positive cancer cells
por: Cheng, Lichun, et al.
Publicado: (2017)

Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy
por: Wang, Xiaoguang, et al.
Publicado: (2021)

The value of folate receptor-positive circulating tumour cells as a diagnostic biomarker for lung cancer: a systematic review and meta-analysis
por: Chen, Fangjun, et al.
Publicado: (2023)

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
por: Jiang, Tao, et al.
Publicado: (2017)

Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
por: Stokke, Kristin, et al.
Publicado: (2022)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness
por: Zhou, Qianjun, et al.
Publicado: (2019)

Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer
por: Wang, Lin, et al.
Publicado: (2017)

Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
por: Lian, Shenyi, et al.
Publicado: (2021)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy
por: Zhang, Ling, et al.
Publicado: (2012)

The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy
por: Huang, Yujing, et al.
Publicado: (2016)

Prognostic value of PD‐L1 expression in combination with CD8(+) TILs density in patients with surgically resected non‐small cell lung cancer
por: Yang, Hui, et al.
Publicado: (2017)

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
por: Yu, Xiaofei, et al.
Publicado: (2021)

Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients
por: Li, Hang, et al.
Publicado: (2021)

Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Alama, Angela, et al.
Publicado: (2017)

Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors
por: Liu, Sangtian, et al.
Publicado: (2020)

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
por: Zhou, Juan, et al.
Publicado: (2019)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
por: He, Man, et al.
Publicado: (2021)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
por: Cuppini, Lucia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ks3gpqe4u4ie5j41c2cqg1v9kk